Literature DB >> 10756214

Chronic urticaria.

M Greaves1.   

Abstract

Chronic urticaria remains a major problem in terms of etiology, investigation, and management. It is important to identify patients in whom physical urticaria is the principal cause of disability. Once confirmed by appropriate challenge testing, no further investigation is required. Urticarial vasculitis (UV) is a major differential diagnosis of "idiopathic" urticaria (CIU). I perform biopsy of most patients in this category because UV cannot be considered confirmed in the absence of histologic evidence. Patients with confirmed UV need to be thoroughly investigated for paraproteins, lupus erythematosus hepatitis B and C, and inflammatory bowel disease. Of patients with CIU, a few (<5%) prove to have food additive reactivity confirmed by placebo-controlled challenge testing. There is no convincing evidence of the involvement of Helicobacter pylori or parasite infestation as a cause of chronic urticaria, although H pylori could have an indirect role. Recently it has become clear that 27% to 50% of patients with CIU have functional autoantibodies directed against the alpha-chain of the high-affinity IgE receptor or less commonly against IgG. These antibodies, whose involvement has now been independently confirmed in several centers, are identified by autologous serum skin testing and confirmed by histamine release studies or immunoblotting. Their removal (by intravenous Ig or plasmapheresis) or treatment by cyclosporine has proved highly beneficial in severely affected patients. However, the routine treatment of all CIU patients, irrespective of etiology, remains the judicious use of H(1) antihistamines.

Entities:  

Mesh:

Year:  2000        PMID: 10756214     DOI: 10.1067/mai.2000.105706

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  79 in total

Review 1.  Treatment of patients with chronic idiopathic urticaria.

Authors:  Brett E Stanaland
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

Review 2.  Chronic urticaria and/or angioedema.

Authors:  Roger W Fox
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

Review 3.  The safety and efficacy of desloratadine for the management of allergic disease.

Authors:  William E Berger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  Chronic urticaria and thyroid auto-immunity.

Authors:  Marie-Sylvie Doutre
Journal:  Clin Rev Allergy Immunol       Date:  2006-02       Impact factor: 8.667

Review 5.  The urticarias: pathophysiology and management.

Authors:  Clive Grattan
Journal:  Clin Med (Lond)       Date:  2012-04       Impact factor: 2.659

Review 6.  Chronic Urticaria: Comparisons of US, European, and Asian Guidelines.

Authors:  S Shahzad Mustafa; Mario Sánchez-Borges
Journal:  Curr Allergy Asthma Rep       Date:  2018-05-24       Impact factor: 4.806

Review 7.  Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications.

Authors:  Massimo Cugno; Angelo V Marzano; Riccardo Asero; Alberto Tedeschi
Journal:  Intern Emerg Med       Date:  2009-12-01       Impact factor: 3.397

8.  Autoantibodies in chronic idiopathic urticaria and nonurticarial systemic autoimmune disorders.

Authors:  Christine B Cho; Shahan A Stutes; Michelle L Altrich; Stacy P Ardoin; Gary Phillips; Princess U Ogbogu
Journal:  Ann Allergy Asthma Immunol       Date:  2013-01       Impact factor: 6.347

Review 9.  Evaluating chronic urticaria patients for allergies, infections, or autoimmune disorders.

Authors:  Y C Wai; Gordon L Sussman
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

10.  Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria.

Authors:  Yuumi Nakamura; Naotomo Kambe; Megumu Saito; Ryuta Nishikomori; Ryuta Nishikomiri; Yun-Gi Kim; Makoto Murakami; Gabriel Núñez; Hiroyuki Matsue
Journal:  J Exp Med       Date:  2009-04-13       Impact factor: 17.579

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.